Current status of licensed calcitonin gene-related peptide drugs in the UK
| Drug | Dose | Status |
|---|---|---|
| Erenumab (Aimovig®) | 70–140 mg monthly | Submitted and rejected by the National Institute for Health and Care Excellence (NICE) on the grounds of cost effectiveness. Accepted by the Scottish Medicines Consortium for chronic migraine, in whom three agents have failed |
| Fremanezumab (Ajovy®) | 225 mg monthly or 675 mg 3-monthly | Accepted by the Scottish Medicines Consortium and NICE for chronic migraine, in whom three agents have failed |
| Galcanezumab (Emgality®) | 120–240 mg monthly | Awaiting NICE submission |